Fool - Investing News·16h ago
5 Dividend Kings Long-Term Investors Should Own for the Next 20 YearsInvestors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Johnson & Johnson(JNJ)Earnings, Financials & Key Ratios
JNJ•NYSE
$267.24
24.2× P/E·Price updated Jul 7, 2026
AboutJohnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.Show more
- Revenue$94.19B+6.0%
- EBITDA$33.1B+12.2%
- Net Income$26.8B+90.6%
- EPS (Diluted)11.03+90.5%
- Gross Margin72.78%+5.4%
- EBITDA Margin35.14%+5.8%
- Operating Margin27.17%+9.0%
- Net Margin28.46%+79.7%
- ROE35.03%+74.7%
JNJ Price & Volume
Johnson & Johnson (JNJ) stock price & volume — 10-year historical chart
Loading chart...
Strategic Portfolio Transformation Drives Revenue Growth Momentum
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Strong
Financial:Fortress
Cash Flow:Mixed
Primary Risk:Litigation and Patent Cliffs
Key Thesis Takeaways
- Johnson & Johnson is successfully pivoting toward high-growth MedTech and Innovative Medicine, evidenced by a revenue growth acceleration to 9.9% in 2026Q1.
- While the company maintains a fortress balance sheet with $21.7B in cash, investors should monitor the impact of persistent talc litigation on net income volatility and capital allocation.
- The aggressive acquisition strategy, which has increased goodwill to $48.6B, warrants further investigation into the long-term integration risks of these specialized assets.
Verdict Logic
while the company shows accelerating top-line growth of 9.9% in 2026Q1, the current P/E of 23.09 and ongoing litigation-driven cash flow volatility suggest a cautious entry point.
JNJ Growth Metrics
Johnson & Johnson (JNJ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3%
5 Years2.67%
3 Years5.6%
TTM7.87%
Profit CAGR
10 Years5.69%
5 Years12.74%
3 Years14.32%
TTM-3.53%
EPS CAGR
10 Years7.25%
5 Years14.89%
3 Years17.9%
TTM-3.78%
Return on Capital
10 Years17.04%
5 Years17.2%
3 Years18.26%
Last Year18.62%
JNJ Recent Earnings
Johnson & Johnson (JNJ) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 14, 2026Metric
Actual
Est
EPS
$2.70+0.7%
$2.68
Rev
$24.1B+1.9%
$23.6B
Q1 2026
Jan 21, 2026Metric
Actual
Est
EPS
$2.46+0.0%
$2.46
Rev
$24.6B+1.7%
$24.1B
Q4 2025
Oct 14, 2025Metric
Actual
Est
EPS
$2.80+1.4%
$2.76
Rev
$24.0B+1.0%
$23.8B
Q3 2025
Jul 16, 2025Metric
Actual
Est
EPS
$2.77+3.4%
$2.68
Rev
$23.7B+3.9%
$22.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 14, 2026 | $2.70vs $2.68+0.7% | $24.1Bvs $23.6B+1.9% |
| Q1 2026 | Jan 21, 2026 | $2.46vs $2.46+0.0% | $24.6Bvs $24.1B+1.7% |
| Q4 2025 | Oct 14, 2025 | $2.80vs $2.76+1.4% | $24.0Bvs $23.8B+1.0% |
| Q3 2025 | Jul 16, 2025 | $2.77vs $2.68+3.4% | $23.7Bvs $22.9B+3.9% |
Based on last 12 quarters of dataView full earnings history →
Latest JNJ News
Recent stock market news and headlines for Johnson & Johnson (JNJ)
Proactive Investors - Finance·22h ago
AtaiBeckley set to unlock value from positive depression therapy trial results, says JefferiesAtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) could see increased investor attention as it approaches Phase IIb data for its oral DMT-based therapy VLS-01,...
Proactive Investors - Finance·22h ago
Nasdaq down as chip stocks sell off after Samsung earnings12:30pm: SpaceX set to join Nasdaq 100 SpaceX is set to join the Nasdaq 100 later today, marking another milestone just weeks after its IPO. The company now...
247 Wallst·1 day ago
The $1,500-A-Month Portfolio: Conservative, Moderate, And High-Yield Paths ComparedReplacing $1,500 a month in portfolio income looks simple until yield enters the equation. At a 3.5% yield, you need roughly $514,000 invested. At 6%, the target falls to $300,000. At 10%, it drops to $180,000. Those numbers seem to reward the highest-yielding portfolio, but the real question is what you may have to give... The $1,500-A-Month Portfolio: Conservative, Moderate, And High-Yield Paths Compared
Proactive Investors - Finance·1 day ago
Nasdaq slides at open as chip stocks sell off after Samsung earnings10am: Nasdaq falls as chips sell off Wall Street was mixed in early trading, with the Nasdaq losing 1.0% as investors rotated out of AI and semiconductor...
Peers Comparison
Key metrics vs top competitors for Johnson & Johnson (JNJ)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $267.24 | $643.31B | 24.23 | 6.05% | 28.46% | 35.03% | 1.91% | |
| $95.84 | $166.94B | 25.76 | 5.67% | 13.91% | 12.09% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — | |
| $1235.56 | $1.17T | 53.84 | 44.7% | 34.98% | 101.17% | — | |
| $57.97 | $118.36B | 16.80 | -0.22% | 15.01% | 38.96% | — |
Compare JNJ vs Peers
Johnson & Johnson (JNJ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JNJ SEC Filings & Documents
Johnson & Johnson (JNJ) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Jan 21, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when JNJ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
JNJ Frequently Asked Questions
Johnson & Johnson (JNJ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Johnson & Johnson's revenue?
Johnson & Johnson (JNJ) reported $96.36B in revenue for fiscal year 2025. This represents a 346% increase from $21.62B in 1996.
How fast is Johnson & Johnson growing?
Johnson & Johnson (JNJ) grew revenue by 6.0% over the past year. This is steady growth.
Is JNJ profitable?
Yes, Johnson & Johnson (JNJ) is profitable, generating $21.04B in net income for fiscal year 2025 (28.5% net margin).
Dividend & Returns
Does JNJ pay dividends?
Yes, Johnson & Johnson (JNJ) pays a dividend with a yield of 1.91%. This makes it attractive for income-focused investors.
What is JNJ's return on equity?
Johnson & Johnson (JNJ) has a return on equity (ROE) of 35.0%. This is excellent, indicating efficient use of shareholder capital.
What is Johnson & Johnson's free cash flow?
Johnson & Johnson (JNJ) generated $17.80B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.